Sommer C, Häuser W, Alten R, Petzke F, Späth M, Tölle T, Uçeyler N, Winkelmann A, Winter E, Bär KJ (June 2012). "[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]". Schmerz (in German). 26 (3): 297–310. doi:10.1007/s00482-012-1172-2. PMID22760463. S2CID1348989.
Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, Feldman EL, Iverson DJ, Perkins B, Russell JW, Zochodne DW (June 2011). "Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation". Muscle & Nerve. 43 (6): 910–7. doi:10.1002/mus.22092. hdl:2027.42/84412. PMID21484835. S2CID15020212.
Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S (July 2005). "Duloxetine vs. placebo in patients with painful diabetic neuropathy". Pain. 116 (1–2): 109–18. doi:10.1016/j.pain.2005.03.029. PMID15927394. S2CID10291281.
Shkodina AD, Bardhan M, Chopra H, Anyagwa OE, Pinchuk VA, Hryn KV, Kryvchun AM, Boiko DI, Suresh V, Verma A, Delva MY (March 2024). "Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis". CNS Drugs. 38 (3): 205–224. doi:10.1007/s40263-024-01072-5. PMID38421578.
Citrome L, Weiss-Citrome A (January 2012). "A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?". Postgraduate Medicine. 124 (1): 83–93. doi:10.3810/pgm.2012.01.2521. PMID22314118. S2CID20599116.
Li J, Yang L, Pu C, Tang Y, Yun H, Han P (June 2013). "The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis". International Urology and Nephrology. 45 (3): 679–86. doi:10.1007/s11255-013-0410-6. PMID23504618. S2CID10788312.
Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H (June 2009). "A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia". The Clinical Journal of Pain. 25 (5): 365–75. doi:10.1097/ajp.0b013e31819be587. PMID19454869. S2CID12208795.
Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M (July 2007). "Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder". The Journal of Sexual Medicine. 4 (4 Pt 1): 917–29. doi:10.1111/j.1743-6109.2007.00520.x. PMID17627739.
Dueñas H, Brnabic AJ, Lee A, Montejo AL, Prakash S, Casimiro-Querubin ML, Khaled M, Dossenbach M, Raskin J (November 2011). "Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period". International Journal of Psychiatry in Clinical Practice. 15 (4): 242–54. doi:10.3109/13651501.2011.590209. PMID22121997. S2CID23153099.
Štuhec M (September 2015). "Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature". Wien Klin Wochenschr. 127 (17–18): 703–6. doi:10.1007/s00508-014-0688-0. PMID25576334. S2CID184484229.
Demling J, Beyer S, Kornhuber J (January 2010). "To sweat or not to sweat? A hypothesis on the effects of venlafaxine and SSRIs". Med Hypotheses. 74 (1): 155–7. doi:10.1016/j.mehy.2009.07.011. PMID19664885.
Perahia DG, Kajdasz DK, Desaiah D, Haddad PM (December 2005). "Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder". Journal of Affective Disorders. 89 (1–3): 207–12. doi:10.1016/j.jad.2005.09.003. PMID16266753.
Stahl SM, Grady MM, Moret C, Briley M (September 2005). "SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants". CNS Spectrums. 10 (9): 732–47. doi:10.1017/s1092852900019726. PMID16142213. S2CID40022100.
Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S (2005). "The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression". Current Pharmaceutical Design. 11 (12): 1475–93. doi:10.2174/1381612053764805. PMID15892657.
Fric M, Pfuhlmann B, Laux G, Riederer P, Distler G, Artmann S, Wohlschläger M, Liebmann M, Deckert J (July 2008). "The influence of smoking on the serum level of duloxetine". Pharmacopsychiatry. 41 (4): 151–155. doi:10.1055/s-2008-1073173. PMID18651344. S2CID22045964.
Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB (June 2007). "Cytokine imbalance in the pathophysiology of major depressive disorder". Prog Neuropsychopharmacol Biol Psychiatry. 31 (5): 1044–53. doi:10.1016/j.pnpbp.2007.03.004. PMID17433516. S2CID22275879.
Fornaro M, Rocchi G, Escelsior A, Contini P, Martino M (March 2013). "Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds". J Affect Disord. 145 (3): 300–7. doi:10.1016/j.jad.2012.08.007. PMID22981313.
Maciukiewicz M, Marshe VS, Tiwari AK, Fonseka TM, Freeman N, Rotzinger S, Foster JA, Kennedy JL, Kennedy SH, Müller DJ (November 2015). "Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder". Pharmacogenomics. 16 (17): 1919–29. doi:10.2217/pgs.15.136. PMID26556688.
Miyauchi T, Tokura T, Kimura H, Ito M, Umemura E, Sato Boku A, Nagashima W, Tonoike T, Yamamoto Y, Saito K, Kurita K, Ozaki N (July 2019). "Effect of antidepressant treatment on plasma levels of neuroinflammation-associated molecules in patients with somatic symptom disorder with predominant pain around the orofacial region". Hum Psychopharmacol. 34 (4): e2698. doi:10.1002/hup.2698. PMID31125145. S2CID163168228.
Qiu W, Go KA, Wen Y, Duarte-Guterman P, Eid RS, Galea LAM (October 2021). "Maternal fluoxetine reduces hippocampal inflammation and neurogenesis in adult offspring with sex-specific effects of periadolescent oxytocin". Brain Behav Immun. 97: 394–409. doi:10.1016/j.bbi.2021.06.012. PMID34174336. S2CID235620244.
Wong DT, Robertson DW, Bymaster FP, Krushinski JH, Reid LR (1988). "LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug". Life Sciences. 43 (24): 2049–57. doi:10.1016/0024-3205(88)90579-6. PMID2850421.
"Duloxetine". Drugs.com. Archived from the original on 29 September 2018. Retrieved 24 December 2018.
"Duloxetine". Monograph. The American Society of Health-System Pharmacists. Archived from the original on 26 November 2018. Retrieved 24 December 2018.
Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, Feldman EL, Iverson DJ, Perkins B, Russell JW, Zochodne DW (June 2011). "Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation". Muscle & Nerve. 43 (6): 910–7. doi:10.1002/mus.22092. hdl:2027.42/84412. PMID21484835. S2CID15020212.
Sommer C, Häuser W, Alten R, Petzke F, Späth M, Tölle T, Uçeyler N, Winkelmann A, Winter E, Bär KJ (June 2012). "[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]". Schmerz (in German). 26 (3): 297–310. doi:10.1007/s00482-012-1172-2. PMID22760463. S2CID1348989.
Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, Feldman EL, Iverson DJ, Perkins B, Russell JW, Zochodne DW (June 2011). "Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation". Muscle & Nerve. 43 (6): 910–7. doi:10.1002/mus.22092. hdl:2027.42/84412. PMID21484835. S2CID15020212.
Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S (July 2005). "Duloxetine vs. placebo in patients with painful diabetic neuropathy". Pain. 116 (1–2): 109–18. doi:10.1016/j.pain.2005.03.029. PMID15927394. S2CID10291281.
"Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects". Prescrire International. 15 (85): 168–72. October 2006. PMID17121211.
Shkodina AD, Bardhan M, Chopra H, Anyagwa OE, Pinchuk VA, Hryn KV, Kryvchun AM, Boiko DI, Suresh V, Verma A, Delva MY (March 2024). "Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis". CNS Drugs. 38 (3): 205–224. doi:10.1007/s40263-024-01072-5. PMID38421578.
Citrome L, Weiss-Citrome A (January 2012). "A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?". Postgraduate Medicine. 124 (1): 83–93. doi:10.3810/pgm.2012.01.2521. PMID22314118. S2CID20599116.
Li J, Yang L, Pu C, Tang Y, Yun H, Han P (June 2013). "The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis". International Urology and Nephrology. 45 (3): 679–86. doi:10.1007/s11255-013-0410-6. PMID23504618. S2CID10788312.
Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H (June 2009). "A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia". The Clinical Journal of Pain. 25 (5): 365–75. doi:10.1097/ajp.0b013e31819be587. PMID19454869. S2CID12208795.
Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M (July 2007). "Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder". The Journal of Sexual Medicine. 4 (4 Pt 1): 917–29. doi:10.1111/j.1743-6109.2007.00520.x. PMID17627739.
Dueñas H, Brnabic AJ, Lee A, Montejo AL, Prakash S, Casimiro-Querubin ML, Khaled M, Dossenbach M, Raskin J (November 2011). "Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period". International Journal of Psychiatry in Clinical Practice. 15 (4): 242–54. doi:10.3109/13651501.2011.590209. PMID22121997. S2CID23153099.
Štuhec M (September 2015). "Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature". Wien Klin Wochenschr. 127 (17–18): 703–6. doi:10.1007/s00508-014-0688-0. PMID25576334. S2CID184484229.
Demling J, Beyer S, Kornhuber J (January 2010). "To sweat or not to sweat? A hypothesis on the effects of venlafaxine and SSRIs". Med Hypotheses. 74 (1): 155–7. doi:10.1016/j.mehy.2009.07.011. PMID19664885.
Perahia DG, Kajdasz DK, Desaiah D, Haddad PM (December 2005). "Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder". Journal of Affective Disorders. 89 (1–3): 207–12. doi:10.1016/j.jad.2005.09.003. PMID16266753.
Stahl SM, Grady MM, Moret C, Briley M (September 2005). "SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants". CNS Spectrums. 10 (9): 732–47. doi:10.1017/s1092852900019726. PMID16142213. S2CID40022100.
Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S (2005). "The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression". Current Pharmaceutical Design. 11 (12): 1475–93. doi:10.2174/1381612053764805. PMID15892657.
Fric M, Pfuhlmann B, Laux G, Riederer P, Distler G, Artmann S, Wohlschläger M, Liebmann M, Deckert J (July 2008). "The influence of smoking on the serum level of duloxetine". Pharmacopsychiatry. 41 (4): 151–155. doi:10.1055/s-2008-1073173. PMID18651344. S2CID22045964.
Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB (June 2007). "Cytokine imbalance in the pathophysiology of major depressive disorder". Prog Neuropsychopharmacol Biol Psychiatry. 31 (5): 1044–53. doi:10.1016/j.pnpbp.2007.03.004. PMID17433516. S2CID22275879.
Fornaro M, Rocchi G, Escelsior A, Contini P, Martino M (March 2013). "Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds". J Affect Disord. 145 (3): 300–7. doi:10.1016/j.jad.2012.08.007. PMID22981313.
Maciukiewicz M, Marshe VS, Tiwari AK, Fonseka TM, Freeman N, Rotzinger S, Foster JA, Kennedy JL, Kennedy SH, Müller DJ (November 2015). "Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder". Pharmacogenomics. 16 (17): 1919–29. doi:10.2217/pgs.15.136. PMID26556688.
Miyauchi T, Tokura T, Kimura H, Ito M, Umemura E, Sato Boku A, Nagashima W, Tonoike T, Yamamoto Y, Saito K, Kurita K, Ozaki N (July 2019). "Effect of antidepressant treatment on plasma levels of neuroinflammation-associated molecules in patients with somatic symptom disorder with predominant pain around the orofacial region". Hum Psychopharmacol. 34 (4): e2698. doi:10.1002/hup.2698. PMID31125145. S2CID163168228.
Qiu W, Go KA, Wen Y, Duarte-Guterman P, Eid RS, Galea LAM (October 2021). "Maternal fluoxetine reduces hippocampal inflammation and neurogenesis in adult offspring with sex-specific effects of periadolescent oxytocin". Brain Behav Immun. 97: 394–409. doi:10.1016/j.bbi.2021.06.012. PMID34174336. S2CID235620244.
Wong DT, Robertson DW, Bymaster FP, Krushinski JH, Reid LR (1988). "LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug". Life Sciences. 43 (24): 2049–57. doi:10.1016/0024-3205(88)90579-6. PMID2850421.
Sommer C, Häuser W, Alten R, Petzke F, Späth M, Tölle T, Uçeyler N, Winkelmann A, Winter E, Bär KJ (June 2012). "[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]". Schmerz (in German). 26 (3): 297–310. doi:10.1007/s00482-012-1172-2. PMID22760463. S2CID1348989.
Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, Feldman EL, Iverson DJ, Perkins B, Russell JW, Zochodne DW (June 2011). "Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation". Muscle & Nerve. 43 (6): 910–7. doi:10.1002/mus.22092. hdl:2027.42/84412. PMID21484835. S2CID15020212.
Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S (July 2005). "Duloxetine vs. placebo in patients with painful diabetic neuropathy". Pain. 116 (1–2): 109–18. doi:10.1016/j.pain.2005.03.029. PMID15927394. S2CID10291281.
Citrome L, Weiss-Citrome A (January 2012). "A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?". Postgraduate Medicine. 124 (1): 83–93. doi:10.3810/pgm.2012.01.2521. PMID22314118. S2CID20599116.
Li J, Yang L, Pu C, Tang Y, Yun H, Han P (June 2013). "The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis". International Urology and Nephrology. 45 (3): 679–86. doi:10.1007/s11255-013-0410-6. PMID23504618. S2CID10788312.
Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H (June 2009). "A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia". The Clinical Journal of Pain. 25 (5): 365–75. doi:10.1097/ajp.0b013e31819be587. PMID19454869. S2CID12208795.
Dueñas H, Brnabic AJ, Lee A, Montejo AL, Prakash S, Casimiro-Querubin ML, Khaled M, Dossenbach M, Raskin J (November 2011). "Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period". International Journal of Psychiatry in Clinical Practice. 15 (4): 242–54. doi:10.3109/13651501.2011.590209. PMID22121997. S2CID23153099.
Štuhec M (September 2015). "Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature". Wien Klin Wochenschr. 127 (17–18): 703–6. doi:10.1007/s00508-014-0688-0. PMID25576334. S2CID184484229.
Stahl SM, Grady MM, Moret C, Briley M (September 2005). "SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants". CNS Spectrums. 10 (9): 732–47. doi:10.1017/s1092852900019726. PMID16142213. S2CID40022100.
Fric M, Pfuhlmann B, Laux G, Riederer P, Distler G, Artmann S, Wohlschläger M, Liebmann M, Deckert J (July 2008). "The influence of smoking on the serum level of duloxetine". Pharmacopsychiatry. 41 (4): 151–155. doi:10.1055/s-2008-1073173. PMID18651344. S2CID22045964.
Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB (June 2007). "Cytokine imbalance in the pathophysiology of major depressive disorder". Prog Neuropsychopharmacol Biol Psychiatry. 31 (5): 1044–53. doi:10.1016/j.pnpbp.2007.03.004. PMID17433516. S2CID22275879.
Miyauchi T, Tokura T, Kimura H, Ito M, Umemura E, Sato Boku A, Nagashima W, Tonoike T, Yamamoto Y, Saito K, Kurita K, Ozaki N (July 2019). "Effect of antidepressant treatment on plasma levels of neuroinflammation-associated molecules in patients with somatic symptom disorder with predominant pain around the orofacial region". Hum Psychopharmacol. 34 (4): e2698. doi:10.1002/hup.2698. PMID31125145. S2CID163168228.
Qiu W, Go KA, Wen Y, Duarte-Guterman P, Eid RS, Galea LAM (October 2021). "Maternal fluoxetine reduces hippocampal inflammation and neurogenesis in adult offspring with sex-specific effects of periadolescent oxytocin". Brain Behav Immun. 97: 394–409. doi:10.1016/j.bbi.2021.06.012. PMID34174336. S2CID235620244.
"Duloxetine". Monograph. The American Society of Health-System Pharmacists. Archived from the original on 26 November 2018. Retrieved 24 December 2018.
"Medications for OCD". International OCD Foundation. Archived from the original on 27 January 2024. Retrieved 25 February 2024.